Cargando…

Studying the blood–brain barrier will provide new insights into neurodegeneration – Yes

Detalles Bibliográficos
Autores principales:	Kamphuis, Wouter W, De Vries, Helga E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Controversies in Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029146/ https://www.ncbi.nlm.nih.gov/pubmed/29504448 http://dx.doi.org/10.1177/1352458518754367

Ejemplares similares

Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
por: Cree, Bruce AC
Publicado: (2022)

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes
por: Scalfari, Antonio
Publicado: (2021)

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach – NO
por: Hulst, Hanneke E, et al.
Publicado: (2017)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
por: Mühlau, Mark
Publicado: (2022)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Commentary
por: Hohlfeld, R
Publicado: (2021)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
por: Gastaldi, Matteo, et al.
Publicado: (2023)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2022)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis
por: Thomas, Sarah, et al.
Publicado: (2013)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

How common is truly benign MS in a UK population?
por: Tallantyre, Emma Clare, et al.
Publicado: (2019)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population
por: de Mol, Casper L., et al.
Publicado: (2022)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ejsrn31e36ciol5co1qqc25gj9